Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177

Futu News01:32 · Ratings

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Yahoo Finance01:30

Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating

MT NewswiresDec 23 18:56 · Ratings

Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services

BenzingaDec 20 02:38

Is Quest Diagnostics (NYSE:DGX) Using Too Much Debt?

Simply Wall StDec 20 02:30

Quest Diagnostics Deal Sends Mainz Higher

Seeking AlphaDec 20 01:17